Phase II Study of Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults With Newly Diagnosed, Standard Risk Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 22 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 22 Sep 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 18 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History